CSTL icon

Castle Biosciences

33.45 USD
-0.67
1.96%
At close Updated Nov 14, 4:00 PM EST
Pre-market
After hours
33.45
0.00
0%
1 day
-1.96%
5 days
1.03%
1 month
49.6%
3 months
68.77%
6 months
104.96%
Year to date
19.29%
1 year
8.5%
5 years
-33.43%
10 years
56.31%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823

0
Funds holding %
of 7,277 funds
0
Analysts bullish %
of 3 analysts
0
Positive news %
of 17 articles
Price charts implemented using Lightweight Charts™